Drug intelligence / Profile preview

SGR-6016

Development stage: Preclinical
Lead developer: Schrödinger
Modality: Small Molecules

Overview

SGR-6016 is a structurally distinct, small-molecule inhibitor of the NLRP3 (NLR family pyrin domain containing 3) inflammasome, developed by Schrödinger. The NLRP3 inflammasome is a multi-protein complex that triggers the release of pro-inflammatory cytokines, such as IL-1β and IL-18, in response to cellular stress or infection. Dysregulation of this pathway is implicated in a wide range of inflammatory and autoimmune diseases. SGR-6016 was identified through Schrödinger's computational platform and has demonstrated favorable potency, selectivity, and safety in preclinical models. It is currently in preclinical development for the treatment of inflammatory and cardiometabolic conditions.

Targets

NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)

Beyond the preview

Go deeper on SGR-6016.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SGR-6016.

Explore the full profile